GuruFocus - Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on July 25, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 75,611 shares of the company.
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Over the past year, Stephen Betz has sold a total of 33,000 shares of Crinetics Pharmaceuticals Inc and has not made any purchases of the stock. This recent transaction is part of a broader trend observed within the company, where there have been 34 insider sells and no insider buys over the past year.
Shares of Crinetics Pharmaceuticals Inc were trading at $53.43 on the day of the transaction. The company currently holds a market cap of approximately $4.29 billion.
For further details on the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties can explore the provided links.
This insider sale might interest investors tracking insider behaviors as an indicator of potential future stock performance, although it is essential to consider the broader market and company-specific factors when evaluating such transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This content was originally published on Gurufocus.com
